Drugs / REGN3051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03301090 | Feb 2018 → Jan 2019 | Coronaviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN3051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03301090 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody (mAb)” NCT03301090 ↗ |
| Route | Intravenous | “administered IV in healthy adult volunteers” NCT03301090 ↗ |